EUVIMEDEUVIMED entdecken
Crossref

Fibroblast Activation Protein Targeting Probe with Gly–Pro Sequence for PET of Glioblastoma

Chaoquan Lai iD, Rui Cao iD, Renda Li, Chunfeng He, Xiao Wang, Hui Shi, Chunrong Qu, Kun Qian, Shaoli Song iD, Wen-Hua Chen, Zhen Cheng iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Chaoquan Lai und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, Guangdong 529020, China. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As an important cancer-associated fibroblast-specific biomarker, fibroblast activation protein (FAP) has become an attractive target for tumor diagnosis and treatment. However, most FAP-based radiotracers showed inadequate uptake and short retention in tumors. In this study, we designed and synthesized a novel FAP ligand (DOTA-GPFAPI-04) through assembling three functional moieties: a quinoline-based FAP inhibitor for specifically targeting FAP, a FAP substrate Gly-Pro as a linker for increasing the FAP protein interaction, and a 2,2',2″,2‴-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) chelator for radiolabeling with different radionuclides. The FAP targeting ability of DOTA-GPFAPI-04 was investigated by molecular docking studies. DOTA-GPFAPI-04 was then radiolabeled with 68Ga to give [68Ga]Ga-DOTA-GPFAPI-04 for positron emission tomography (PET) imaging of glioblastoma. [68Ga]Ga-DOTA-GPFAPI-04 exhibited a purity of >98% and high stability analyzed by radio-HPLC in saline and mouse serum. Cell uptake studies demonstrated the targeting specificity of the probe. Further in vivo pharmacokinetic studies in normal mice demonstrated the quick clearance of the probe. Moreover, compared with the widely studied [68Ga]Ga-FAPI-04, [68Ga]Ga-DOTA-GPFAPI-04 showed much higher U87MG tumor uptake values (4.467 ± 0.379 for [68Ga]Ga-DOTA-GPFAPI-04 and 1.267 ± 0.208% ID/g for [68Ga]Ga-FAPI-04 at 0.5 h post-injection, respectively). The area under the curve based on time-activity curve (TAC) analysis for tumor radioactivity in small animal models was 422.5 for [68Ga]Ga-DOTA-GPFAPI-04 and 98.14 for [68Ga]Ga-FAPI-04, respectively, demonstrating that the former had longer tumor retention time. The tumor-to-muscle (T/M) ratio for [68Ga]Ga-DOTA-GPFAPI-04 reached 9.15 in a U87MG xenograft animal model. PET imaging and blocking assays showed that [68Ga]Ga-DOTA-GPFAPI-04 had specific tumor uptake. In summary, this study demonstrates the successful synthesis and evaluation of a novel FAPI targeting probe, [68Ga]Ga-DOTA-GPFAPI-04, with a Gly-Pro sequence. It shows favorable in vivo glioblastoma imaging properties and relatively long tumor retention, highlighting DOTA-GPFAPI-04 as a promising molecular scaffold for developing FAP targeting tumor theranostic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHumansMiceAnimalsGallium RadioisotopesMolecular Docking SimulationPositron-Emission TomographyFibroblastsPositron Emission Tomography Computed TomographyDipeptides

Stichwörter der Autor:innen

FAPIPET imagingfibroblast activation proteinglioblastoma

Substanzen

Gallium RadioisotopesglycylprolineDipeptides

Autor:innen und Institutionen

  • School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, Guangdong 529020, China.
  • State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong 264117, China.

ORCID-Profile: Chaoquan Lai, Rui Cao, Shaoli Song, Zhen Cheng

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Lai, C., Cao, R., Li, R., He, C., Wang, X., Shi, H., Qu, C., Qian, K., Song, S., Chen, W. H., & Cheng, Z. (2023). Fibroblast Activation Protein Targeting Probe with Gly–Pro Sequence for PET of Glioblastoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00248

Vancouver

Lai C, Cao R, Li R, He C, Wang X, Shi H, et al. Fibroblast Activation Protein Targeting Probe with Gly–Pro Sequence for PET of Glioblastoma. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00248

BibTeX
@article{Lai2023,
  author = {Lai, Chaoquan and Cao, Rui and Li, Renda and He, Chunfeng and Wang, Xiao and Shi, Hui and Qu, Chunrong and Qian, Kun and Song, Shaoli and Chen, Wen-Hua and Cheng, Zhen},
  title = {Fibroblast Activation Protein Targeting Probe with Gly–Pro Sequence for PET of Glioblastoma},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00248}
}
Kostenlos starten →